solute carrier family 26 member 2Genealiases: D5S1708 · DTD · DTDST · EDM4 · MST153 · MSTP157
Q-omics provides the consensus-scored SLC26A2 profile across patient tissues and cancer cell-line models. SLC26A2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SLC26A2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SLC26A2 RNA expression shows 20,333 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, COAD, and THYM as cancer lineages where SLC26A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC26A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC26A2 survival associations across molecular data types. SLC26A2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC26A2 RNA expression–survival associations across cancer types. High SLC26A2 expression shows unfavorable associations in KICH, LIHC, UVM and LGG, but favorable associations in KIRC and HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for SLC26A2 RNA expression.
This table summarizes SLC26A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC26A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC26A2 shows lower tumor expression in COAD, KICH, HNSC and LUSC and higher tumor expression in LIHC and UCEC. The COAD box plot shows higher SLC26A2 RNA expression in normal versus tumor tissue (log2 FC = −5.127, t-test p < 0.001).
This table shows molecular features associated with SLC26A2 in patient tissues and cancer cell lines. In patient samples, SLC26A2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC26A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
